Reven Stock

reven.comHealthcareFounded: 1999Funding to Date: $106.23MM

Reven Pharmaceuticals is a biopharmaceutical company developing solutions for those suffering the effects of vascular and metabolic related diseases.

Register for Details

For more details on financing and valuation for Reven, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Reven.

Register Today

Team

Management Team

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
James Ervin
Chief Technology Officer
Peter Lange
Founder, Board Member & Chief Executive Officer
Henk Van Wyk
Chief Scientist

Board Members

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
Peter Lange
Founder, Board Member & Chief Executive Officer

Other companies like Reven in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

New Delhi, India -- (SBWIRE) -- 04/09/2018 -- Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD). It occurs with severe obstructions in the arteries which leads to reduced blood flow to the extremities.
There has been $13.1 billion invested across 1,287 deals so far this year